- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.05. | XFRA 9RP: AUSSETZUNG/SUSPENSION | 281 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLIPIGON PHARMA.... ► Artikel lesen | |
| 04.05. | Lipigon Pharmaceuticals AB - Removal from trading on Nasdaq First North Growth Market | 303 | GlobeNewswire | According to section 2.3.7 of the Nasdaq First North Growth Market Rulebook, an issuer shall be able to demonstrate ongoing business operations.
According to section 8.2.7 of the Nasdaq First... ► Artikel lesen | |
| LIPIGON PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 20.04. | The observation status for Lipigon Pharmaceuticals AB is updated | 196 | GlobeNewswire | On February 20, 2026, the shares in Lipigon Pharmaceuticals AB (the "Company") were given observation status with reference to information that the Company had limited liquidity and was dependent... ► Artikel lesen | |
| 20.02. | Lipigon Pharmaceuticals AB receives observation status | 599 | GlobeNewswire | On February 16, 2026, Lipigon Pharmaceuticals AB (the "Company") disclosed a press release providing, inter alia, an update regarding the Company's drug candidate Lipisense. The press release also... ► Artikel lesen | |
| 14.10.25 | Lipigon Pharmaceuticals AB: Lipigon Pharmaceuticals reports last patient visit in the three-month follow-up of its Phase II clinical study with Lipisense | 237 | GlobeNewswire (Europe) | Lipigon Pharmaceuticals AB (publ) today announced that the last patient in the company's Phase II clinical study of Lipisense® has completed the three-month follow-up. The study includes a total of... ► Artikel lesen | |
| 06.07.25 | Lipigon Pharmaceuticals AB: Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense | 374 | GlobeNewswire (Europe) | This press release is an English translation of the Swedish press release published by Lipigon Pharmaceuticals AB on 2025-06-23.
Lipigon Pharmaceuticals AB announced today that the last patient has... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CHRISTINA LAKE CANNABIS | 0,014 | 0,00 % | Christina Lake Cannabis Corp: Christina Lake investor Milia acquires 5.03M shares | ||
| PSYCHED WELLNESS | 0,005 | 0,00 % | Psyched Wellness Ltd.: Psyched Wellness Highlights U.S. Federal Policy Momentum Supporting Psychedelic Sector | Toronto, Ontario--(Newsfile Corp. - April 23, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution... ► Artikel lesen | |
| GREENRISE GLOBAL BRANDS | 0,005 | -100,00 % | CSE Bulletin: Suspensions - Adastra Holdings Ltd., CAT Strategic Metals Corporation, Greenrise Global Brands Inc., StickIt Technologies Inc. | Le 12 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101... ► Artikel lesen | |
| NUMINUS WELLNESS | 0,027 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 23.04.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.04.2026ISIN NameAU000000BMG3 BMG... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,030 | 0,00 % | BetterLife Pharma Inc. - 20-F, Annual and transition report of foreign private issuers | ||
| MEDIPHARM LABS | 0,050 | +3,09 % | Medipharm Labs Corp: Medipharm Labs reminds holders of June 17 AGSM | ||
| ADDEX THERAPEUTICS | 0,046 | 0,00 % | Addex Therapeutics: Addex Reports Full Year 2025 Financial Results and Provides Corporate Update | GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued to reposition dipraglurant mGlu5 NAM for brain injury... ► Artikel lesen | |
| PROMINO NUTRITIONAL SCIENCES | 0,018 | +12,50 % | Promino Nutritional Sciences, Inc.: Promino Delivered to Stanley Cup Final Locker Room as Ambassador Jack Eichel Competes for Championship | Burlington, Ontario--(Newsfile Corp. - June 2, 2026) - Promino Nutritional Sciences, Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company"), a leader in muscle health and performance... ► Artikel lesen | |
| ARGENT BIOPHARMA | 0,015 | -9,09 % | ARGENT BIOPHARMA LIMITED: Long Term Aquiol Licensing and Supply Agreement | ||
| CANNABIST COMPANY | 0,020 | 0,00 % | XFRA VW5: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCANNABIST CO.HLDG.INC... ► Artikel lesen | |
| IANTHUS CAPITAL | 0,001 | 0,00 % | iAnthus Capital Holdings, Inc.: iAnthus Reports Fiscal First Quarter 2026 Financial Results | NEW YORK and TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- iAnthus Capital Holdings, Inc. ("iAnthus" or the "Company") (CSE: IAN, OTCID: ITHUF), which owns, operates, and partners with regulated cannabis... ► Artikel lesen | |
| CENTR BRANDS | 0,001 | 0,00 % | Centr Brands Corp (2): Centr Brands arranges $100,000 debenture offering | ||
| RESTART LIFE SCIENCES | 0,054 | -0,92 % | Restart Life Sciences Corp.: Restart Life Sciences Closes Dedicated Purchase Order Financing Private Placement; CEO Subscribes for 50% of Offering | Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that... ► Artikel lesen | |
| AYR WELLNESS | 0,050 | 0,00 % | AYR Wellness Announces Closing of Florida, New Jersey and Nevada Operations Transfer to Arboretum | ||
| NEURIZON THERAPEUTICS | 0,033 | +3,12 % | NEURIZON THERAPEUTICS LIMITED: Application for quotation of securities - NUZ |
Das Unternehmen LIPIGON PHARMACEUTICALS AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,000 Euro und damit -100,00 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIPIGON PHARMACEUTICALS AB finden Sie auf Wallstreet Online.